Structure-based pharmacophore modelling for ErbB4-kinase inhibition: a systematic computational approach for small...

Area of Science:

• Oncology
• Biochemistry
• Drug Discovery

Background:

• ErbB2 kinase is a primary target in 20% of breast cancers.
• ErbB2-resistant breast cancers can become dependent on ErbB4.
• Targeting ErbB4 offers a strategy to overcome resistance to ErbB2 inhibitors.

Purpose of the Study:

• To identify novel small molecule inhibitors of ErbB4 kinase.
• To explore ErbB4 as a therapeutic target in resistant breast cancer.
• To provide a foundation for rational drug design against ErbB4-dependent cancers.

Main Methods:

• Structure-based pharmacophore modeling using ErbB4-lapatinib crystal structures.
• Molecular docking and MM-GBSA calculations for binding affinity.
• Virtual screening of the Chembl database for potential drug candidates.
• ADMET profiling to assess pharmacokinetic and toxicity properties.

Main Results:

• Identified critical pharmacophoric features for ErbB4 inhibition.
• Screened the Chembl database to discover potential small molecule inhibitors.
• Assessed ADMET profiles of 11 shortlisted drug candidates.
• Chembl310724, Chembl521284, and Chembl4168686 demonstrated potent ErbB4 inhibition with significant binding free energies (-99.84, -89.42, and -86.06 kcal/mol, respectively).

Conclusions:

• The study successfully identified promising novel ErbB4 kinase inhibitors.
• The integrated computational approach provides a robust framework for designing targeted therapies.
• These findings lay the groundwork for developing new treatments for ErbB4-dependent breast cancers, particularly those resistant to ErbB2 inhibitors.